Cardiotoxicity – current guidelines

Czech version

Authors: R. Pudil
Authors‘ workplace: I. interní kardioangiologická klinika LF UK a FN Hradec Králové
Published in: Kardiol Rev Int Med 2017, 19(1): 30-33

Overview

The article presents a summary of essential diagnostic and therapeutic procedures in patients who are undergoing anti-cancer therapy, as recommended by the European Society of Cardiology. It deals with the basic clinical manifestations of cardiotoxicity: myocardial dysfunction and heart failure, coronary artery disease, valvular disease, arrhythmias and changes in QT interval, arterial hypertension, thromboembolism, stroke and peripheral artery disease, pulmonary hypertension and impairment pericardium.

Keywords:
cardiotoxicity –⁠ cardio-oncology –⁠ heart failure –⁠ arrhythmias –⁠ guidelines

Sources

1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37(36): 2768 –⁠ 2801.

2. Elbl L. Pozdní následky kardiotoxicity. Kardiol Rev Int Med 2017; 19 (1): 22–29.